GAITHERSBURG, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics (“Remedy Plan”), a clinical stage pharmaceutical company unlocking the therapeutic potential of NAMPT inhibition, ...
GAITHERSBURG, Md., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics (“Remedy Plan”), a clinical-stage biotech company focused on developing NAMPT inhibitors for patients with hematological ...
Data on RPT1G, a clinical drug candidate for the treatment of solid and hematological malignancies, that selectively kills cancer cells and is thousands-fold better tolerated by healthy cells than ...
GAITHERSBURG, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics, a privately-held clinical-stage pharmaceutical company transforming the field of NAMPT inhibition, announced today the ...
Financing includes participation from Schooner Capital, Alexandria Venture Investments, and other existing investors Investment accelerates advancement of RPT1G, a novel NAMPT inhibitor, into a Phase ...
RPT1G is the first well-tolerated NAMPT inhibitor, demonstrating safety in healthy volunteers at single and multiple ascending dose levels. Target engagement data indicate that RPT1G inhibits NAMPT in ...
Company to present Trial in Progress design from ongoing Phase 1 study of RPT1G in patients with advanced myeloid cancers RPT1G anti-tumor efficacy data in pre-clinical non-Hodgkin lymphoma models to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback